Esperion Therapeutics, Inc. (ESPR)
| Market Cap | 325.50M |
| Revenue (ttm) | 116.33M |
| Net Income (ttm) | -209.25M |
| Shares Out | 170.42M |
| EPS (ttm) | -2.03 |
| PE Ratio | n/a |
| Forward PE | 1.03 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,502,128 |
| Open | 1.970 |
| Previous Close | 1.950 |
| Day's Range | 1.840 - 1.970 |
| 52-Week Range | 0.700 - 3.400 |
| Beta | 0.82 |
| Analysts | Strong Buy |
| Price Target | 9.33 (+388.48%) |
| Earnings Date | May 7, 2024 |
About ESPR
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products als... [Read more]
Full Company ProfileFinancial Performance
In 2023, ESPR's revenue was $116.33 million, an increase of 54.14% compared to the previous year's $75.48 million. Losses were -$209.25 million, -10.45% less than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ESPR stock is "Strong Buy." The 12-month stock price forecast is $9.33, which is an increase of 388.48% from the latest price.
News
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
– Patients With Obesity Who Took NEXLETOL Were 23% Less Likely to Experience a Major Adverse Cardiovascular Event (MACE-4) Compared to Placebo –
Esperion Therapeutics (ESPR) CEO on Cholesterol Lowering Medications
Esperion Therapeutics (ESPR) specializes in cholesterol lowering medications. President and CEO Sheldon Koenig joins Nicole Petallides to give an overview of the company.
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
ANN ARBOR, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced that Sheldon Koenig, President and CEO, will ring the Nasdaq Stock Market (Nasdaq) opening bell at 9:30 a.m...
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
ANN ARBOR, Mich., March 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the 23rd Annual Needham Virtual Healthcare Conference. Sheldon Koenig, President and C...
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
ANN ARBOR, Mich., March 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the acceptance of three CLEAR ( C holesterol L owering via B e mpedoic acid, an A CL-Inhibiting R egimen) ...
U.S. FDA Approves Broad New Labels for Esperion's NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
ANN ARBOR, Mich.--(BUSINESS WIRE)--Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL® (bempedoic ac...
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
– New Labels Expand Treatable Population to ~70 Million Patients in U.S. – – First LDL-C Lowering Non-Statin Indicated for Primary Prevention Patients – – Approvals Based on Positive CLEAR Outcomes Da...
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
– Positive CHMP Opinions Are Based On The Analyses Of The Phase 3 Of The CLEAR (Cholesterol Lowering via Bempedoic Acid, an ATP Citrate Lyase (ACL)-Inhibiting Regimen) Outcomes Trial 1 –
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
– FY23 U.S. Net Product Revenue Grew 40% Y/Y to $78.3 Million; FY23 Total Revenue Grew 54% Y/Y to $116.3 Million –
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on February 13, 2024, the Company granted 66 new employees 204,900 restricted stock units (RSUs) under...
Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
ANN ARBOR, Mich., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2023 financial results before the market opens on Tuesday, Febr...
RFK, Esperion Therapeutics Announce 2024 Promotional Schedule
NEXLETOL and NEXLIZET to Ride Along RFK Mustangs in Four Races in 2024 NEXLETOL and NEXLIZET to Ride Along RFK Mustangs in Four Races in 2024
This late-January stock-trading pattern has been a winner in 30 of the past 38 years
The stock market, as measured by the S&P 500 index SPX, has broken out strongly to the upside, trading at new intraday and closing highs. The breakout came on Jan. 19, over the 4,800 level.
Esperion Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
ANN ARBOR, Mich., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”, “we”, “us” or “our”) (Nasdaq: ESPR) announced today the closing of its previously announced underwritten pu...
Esperion Announces Pricing of $85.1 Million Public Offering of Common Stock
ANN ARBOR, Mich., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”, “we”, “us” or “our”) (Nasdaq: ESPR) announced today the pricing of its previously announced underwritten pu...
Esperion Announces Proposed Public Offering of Common Stock
ANN ARBOR, Mich., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”, “we”, “us” or “our”) (Nasdaq: ESPR) announced today that it has commenced an underwritten public offering o...
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation
Esperion Therapeutics, Inc. (NASDAQ: ESPR) and Daiichi Sankyo Europe GmbH (DSE) the European headquarter organization of the Japanese pharmaceutical company Daiichi Sankyo Co., Ltd. (TSE: 4568), annou...
U.S. FDA Updates LDL-C Lowering Indication for Esperion's NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
– Updated Label Adds Primary Hyperlipidemia, Removes Maximally Tolerated Statin Requirement, Removes Limitation of Use –
Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023
– A Prespecified, Exploratory Analysis of Participants Reports Those with Higher Baseline Inflammation More Likely to Experience a Major Cardiovascular Event (MACE), Cardiovascular Death, and All-Caus...
Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023
– Data from Randomized Control Trial Will Advance Evidence for Evaluation and Treatment of Heart Disease by Studying Actual Disease: Atherosclerosis –
Esperion Reports Third Quarter 2023 Financial Results
– Q3 U.S. Net Product Revenue Grew 45% Y/Y to $20.3 Million; Q3 Total Revenue Grew 79% Y/Y to $34.0 Million – – Q3 Retail Prescription Equivalents Grew 33% Y/Y and 8% Q/Q, Demonstrating Sustained Mome...
Esperion to Participate in Jefferies London Healthcare Conference
ANN ARBOR, Mich., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the Jefferies London Healthcare Conference. Sheldon Koenig, President and Chief Executi...
American College of Cardiology Program to Increase Cholesterol Screenings
Quality Improvement and Education Program sponsored by Amgen, Esperion to improve adherence to guideline recommendations for managing LDL
Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference
ANN ARBOR, Mich., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference. Sheldon Koenig, President...
Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023
– In total cardiovascular event analysis, bempedoic acid shows 20% risk reduction in MACE-4 and 17% risk reduction in MACE-3 –